Fact CheckerSign in

NCT05718986Not yet recruiting

Familial B-cell Lymphoproliferative Disorders

Epidemiology of Familial B-cell Lymphoproliferative Disorders

Source: ClinicalTrials.gov · Last updated 8 May 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
30 Jan 2023
Start date
Jun 2024
Primary completion date
Dec 2028
Lead sponsor
University of Haifa
NCT number
NCT05718986

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From Jun 2024 to the primary completion date, Dec 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Pregnant women, special populations and those lacking judgment will not be included

Who the study is looking for

  • Patient inclusion criteria:
    • Patients must have LPD and must have a family history of LPD. LPD patients who signed an informed consent to participate in the study.
    • Criteria for the inclusion of relatives of patients:
    • Relatives must be related by blood to LPD patients or unrelated (for control group).
    • Relatives who signed an informed consent to participate in the study.

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.